CN117603885B - 一种副干酪乳杆菌lp-116及其在制备调节肠道屏障受损产品中的应用 - Google Patents
一种副干酪乳杆菌lp-116及其在制备调节肠道屏障受损产品中的应用 Download PDFInfo
- Publication number
- CN117603885B CN117603885B CN202410069815.9A CN202410069815A CN117603885B CN 117603885 B CN117603885 B CN 117603885B CN 202410069815 A CN202410069815 A CN 202410069815A CN 117603885 B CN117603885 B CN 117603885B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- microbial preparation
- intestinal barrier
- inactivated
- lps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 73
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 68
- 230000007358 intestinal barrier function Effects 0.000 title claims abstract description 28
- 210000005027 intestinal barrier Anatomy 0.000 title claims abstract description 22
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 8
- 230000006378 damage Effects 0.000 title abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 36
- 239000006041 probiotic Substances 0.000 claims abstract description 19
- 235000018291 probiotics Nutrition 0.000 claims abstract description 19
- 230000000813 microbial effect Effects 0.000 claims description 74
- 239000000203 mixture Substances 0.000 claims description 10
- 229920001202 Inulin Polymers 0.000 claims description 9
- 229920002774 Maltodextrin Polymers 0.000 claims description 9
- 239000005913 Maltodextrin Substances 0.000 claims description 9
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 9
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 9
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 9
- 229940029339 inulin Drugs 0.000 claims description 9
- 229940035034 maltodextrin Drugs 0.000 claims description 9
- 235000013406 prebiotics Nutrition 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 8
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims 6
- 241001052560 Thallis Species 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 abstract description 56
- 239000002158 endotoxin Substances 0.000 abstract description 56
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 56
- 108090000623 proteins and genes Proteins 0.000 abstract description 27
- 102000004169 proteins and genes Human genes 0.000 abstract description 20
- 230000014509 gene expression Effects 0.000 abstract description 18
- 241000894006 Bacteria Species 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 5
- 210000002490 intestinal epithelial cell Anatomy 0.000 abstract description 5
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 abstract description 4
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 abstract description 4
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 abstract description 4
- 238000012404 In vitro experiment Methods 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 35
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 19
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 18
- 230000001580 bacterial effect Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 11
- 102000000591 Tight Junction Proteins Human genes 0.000 description 10
- 108010002321 Tight Junction Proteins Proteins 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 108020004465 16S ribosomal RNA Proteins 0.000 description 8
- 102000004162 Claudin-1 Human genes 0.000 description 8
- 108090000600 Claudin-1 Proteins 0.000 description 8
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 8
- 108090000304 Occludin Proteins 0.000 description 8
- 230000000770 proinflammatory effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000003940 Occludin Human genes 0.000 description 7
- 239000013553 cell monolayer Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 101710198035 Myosin light chain kinase, smooth muscle Proteins 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241001608472 Bifidobacterium longum Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 102000005747 Transcription Factor RelA Human genes 0.000 description 3
- 108010031154 Transcription Factor RelA Proteins 0.000 description 3
- 229940009291 bifidobacterium longum Drugs 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000016349 Myosin Light Chains Human genes 0.000 description 2
- 108010067385 Myosin Light Chains Proteins 0.000 description 2
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000573526 Homo sapiens Membrane protein MLC1 Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100026290 Membrane protein MLC1 Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 208000037817 intestinal injury Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- -1 p-NFk B Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种副干酪乳杆菌LP‑116及其在制备调节肠道屏障受损产品中的应用,本发明从自然发酵的东北酸菜中分离筛选一株副干酪乳杆菌LP‑116,并通过体外实验检测了副干酪乳杆菌(活菌)和经过热灭活副干酪乳杆菌(后生元)菌粉对肠道屏障功能的调节影响,利用Caco‑2细胞建立肠上皮细胞模型并通过脂多糖LPS诱导炎症,申请人发现通过采用灭活副干酪乳杆菌LP‑116冻和灭活LGG益生菌冻干粉进行复配,可以有效改善经LPS诱导的Caco‑2细胞中紧密蛋白和炎症因子的表达。
Description
技术领域
本发明涉及微生物制剂技术领域,具体涉及一种副干酪乳杆菌LP-116及其在制备调节肠道屏障受损产品中的应用。
背景技术
关于益生菌的共识定义在FAO/WHO(2001)发表过,益生菌是指“当摄入足够数量时,对宿主产生健康益处的活性微生物”。这一定义强调了益生菌必须满足其为“活”的要求。益生菌在早些年主要是以活菌的形式使用,但活菌制剂可能存在潜在的安全隐患,并且不能与抗生素混合使用,易受加工、储存以及动物消化道酸性环境等条件的影响而不稳定。随着人类对益生菌的研究范围和功能的扩大深入,研究者们发现不仅活菌能够发挥益生功能,有一些“非活菌”组分也表现出明显的促进健康的作用,如灭活的菌体细胞、菌体死亡后溶解释放的成分,以及细菌的代谢产物等,其中菌体成分包括脂磷壁酸、细胞表面蛋白、肽聚糖、荚膜多糖、菌毛、鞭毛等,代谢产物包括酶、多肽类、短链脂肪酸、胞外多糖等,这些具有促进健康功效的灭活菌和代谢物均属于“后生元”的范畴。为了统一后生元的定义,2021年5月,国际益生菌和益生元科学协会(ISAPP)发表了后生元(Postbiotics)的共识声明:后生元是指对宿主健康有益的无生命微生物和/或其成分的制剂。
人体肠道具有复杂的微环境,肠道屏障的存在有助于肠道结构的保存,而全世界有超过1000万人受到溃疡性结肠炎和克罗恩病的困扰。研究表明肠道菌群失调和肠道上皮屏障功能障碍与UC和CD的发生有直接关系,当肠道屏障受损时,局部免疫被激活,紧密连接(tight junction,TJ)蛋白结构发生改变,导致细胞因子失衡,介导肠道通透性降低,细胞间相互作用形成的TJ蛋白是肠上皮细胞的主要防御屏障;同时,肌球蛋白轻链激酶(myosinlight chain kinase,MLCK)与TJ蛋白相互作用,调节上皮细胞通透性,维持肠道功能的完整性;MLCK介导肌球蛋白轻链(myosin light chain,MLC)磷酸化(p-MLC),导致TJ蛋白的破坏和肠上皮细胞通透性的增加。既往研究表明,肠道屏障损伤可引起炎症和肠道高蠕动,进而导致炎症性肠病的发病,因此,保持肠道屏障的完整性至关重要。
发明内容
针对现有技术的不足,本发明的目的在于提供一种副干酪乳杆菌LP-116及其在制备调节肠道屏障受损产品中的应用。
为了实现上述目的,本发明采取如下技术方案:
一种副干酪乳杆菌LP-116,该菌株保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏号为CGMCC NO.26441,保藏地址为北京市朝阳区北辰西路1号院3号,拉丁文名称为Lactobacillus paracasei。
本发明还提供一种调节肠道屏障受损的微生物制剂,包括副干酪乳杆菌LP-116和鼠李糖乳杆菌GG株(LGG益生菌)。
优选的,副干酪乳杆菌LP-116和鼠李糖乳杆菌GG株的重量比为1-3:1。
优选的,微生物制剂的活性成分为副干酪乳杆菌LP-116的灭活型菌体以及鼠李糖乳杆菌GG株的灭活型菌体。
优选的,所述微生物制剂为益生菌冻干粉,其中益生菌为副干酪乳杆菌LP-116和鼠李糖乳杆菌GG株;还包括益生元,其中益生元包括麦芽糊精、菊粉和低聚半乳糖。。
优选的,益生菌冻干粉和益生元的质量比为4-6:4-6。
优选的,麦芽糊精、菊粉和低聚半乳糖的质量比为1-2:1-2:1。
优选的,所述微生物的剂型包括片剂、口服液或胶囊剂。
与现有技术相比,本发明具有如下有益效果:
本发明从自然发酵的东北酸菜中分离筛选一株副干酪乳杆菌LP-116,并通过体外实验检测了副干酪乳杆菌(活菌)和经过热灭活副干酪乳杆菌(后生元)菌粉对肠道屏障功能的调节影响,利用Caco-2细胞建立肠上皮细胞模型并通过脂多糖(LPS)诱导炎症,申请人发现通过采用灭活副干酪乳杆菌LP-116和灭活鼠李糖乳杆菌GG株冻干粉进行复配,可以有效改善经LPS诱导的Caco-2细胞中紧密蛋白和炎症因子的表达。
附图说明
图1为副干酪乳杆菌LP-116的扫描电镜图;
图2为副干酪乳杆菌LP-116的24小时生长曲线图;
图3为微生物制剂对Caco-2细胞活性的影响图;
图4为微生物制剂对肠上皮屏障细胞间跨膜电阻和通透性影响图;
图5为微生物制剂对Caco-2细胞促炎症因子水平的影响图;
图6为微生物制剂对Caco-2细胞内目标蛋白表达水平影响图;
图7为微生物制剂的炎症因子及ZO-1、claudin-1、occludin基因表达图;
图8为微生物制剂1改善肠道损伤的效果图;
图9为微生物制剂1改善肠道炎症反应的效果图。
具体实施方式
以下通过具体较佳实施例对本发明作进一步详细说明,但本发明并不仅限于以下的实施例。
需要说明的是,无特殊说明外,本发明中涉及到的化学试剂均通过商业渠道购买。
本发明提供的一种副干酪乳杆菌(LP-116),该菌菌株已于2023年1月9号保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏号为CGMCC NO.26441,保藏地址为北京市朝阳区北辰西路1号院3号,拉丁文名称为Lactobacillus paracasei。
本发明还提供了副干酪乳杆菌(LP-116)的分离纯化方法,按照以下步骤进行:
(一)样品采集
本发明所涉及的副干酪乳杆菌(LP-116)是从自然发酵的东北酸菜分离获得,采样地为黑龙江省绥化市。取新鲜发酵的酸菜汁水100 mL,加入900 mL无菌生理盐水(0.9%,w/v),充分混匀即获得采集样品。
(二)乳酸菌富集
按照1%(v/v)接种量,接种到10mL的MRS肉汤培养基富集培养,37℃严格厌氧培养48~72小时,得到培养液。
MRS肉汤配方(1L):蛋白胨10.0g、牛肉粉5.0g、酵母粉4.0g、葡萄糖20.0g、磷酸氢二钾(K2HPO4)2.0g、柠檬酸三铵(C6H17N3O7)2.0g、乙酸钠(CH3COONa·3H2O)5.0g、硫酸镁(MgSO4·7H2O)0.2g、硫酸锰(MnSO4·4H2O)0.05g、Tween-80 1mL加入去离子水1L,搅拌加热煮沸至完全溶解,分装后于121℃高压灭菌15 min,待冷至常温。
(三)菌株分离
取培养液1 mL,加入9 mL无菌生理盐水(0.9%,w/v)稀释10倍,继续用生理盐水依次稀释到10-2、10-3、10-4、10-5、10-6。吸取0.1 mL不同稀释比例的菌悬液,采用涂布法接种至CaCO3-MRS固体培养基,37℃严格厌氧培养48小时。
CaCO3-MRS固体培养基配方(1L):在MRS肉汤基础上加入琼脂20.0 g,CaCO310 g,去离子水1 L搅拌加热煮沸至充分溶解,分装后于121℃高压灭菌15 min,待冷至60℃左右倒平板,备用。
待平板出现典型菌落后,挑取标准乳酸菌的菌落特征以及产生溶钙圈直径最大的单菌落,进行下一步菌株纯化。
(四)菌株纯化
将挑选出的单菌落进行连续培养三次,培养基内菌落形态一致,并且革兰氏染色为紫色,菌株细胞形态单一,即获得纯培养菌株,接种MRS液体培养基,37℃培养24小时。
(五)菌株保存
分别取900μL纯培养菌株和50%无菌甘油,置于细胞冻存管中充分混匀,-80℃冷冻保存,同时接种至MRS固体斜面培养基保存,送检并鉴定。
副干酪乳杆菌(LP-116)的细菌学特征
一、基本特征
副干酪乳杆菌(LP-116)的基本特征如表1所示:
表1:副干酪乳杆菌LP-116基本特征表
由表1可知,LP-116为革兰氏染色阳性、杆状、无芽孢、接触酶和氧化酶为阴性的菌株,其扫描电子显微镜图如图1所示。
二、生长曲线
LP-116菌株活化:将菌种从-80℃冰箱取出接种在MRS液体培养基中活化24小时,将活化菌株转接于相应MRS固体培养基,37℃恒温培养箱培养48小时,挑取单菌落接种于MRS液体培养基,继续37℃恒温培养18小时提高菌株活力,用于实验备用。
乳酸菌按1%(v/v)接种量接种在MRS肉汤培养基中,在37℃下培养24小时,每隔2小时测定菌液的OD 600值,以时间为横坐标,OD 600值及pH为纵坐标建立菌株的生长曲线。
三、分子生物学鉴定(16S rDNA)
(1)模板制备
取菌液溶于50 μl TaKaRa Lysis Buffer for Microorganism to Direct PCR(货号:D304)中变性后离心取上清作为模板(Template DNA),反应条件:80℃,15 min。
(2)16s rDNA PCR扩增
使用TransGen的PCR扩增试剂2×TransTaq®High Fidelity(HiFi)PCR SuperMixI(货号:AS131),进行PCR扩增。
表2:PCR反应体系表
阴性对照使用1 μl的16S-free H2O替代模板DNA;阳性对照使用1 μl的某已知菌株16S rDNA替代模板DNA。
(3)16s rDNA测序
以1541R-new和27F为引物,使用ABI公司DNA测序仪(型号:3730XL)进行测序。
表3:16s rDNA测序相关引物信息表
将上述菌株进行分子生物学鉴定,副干酪乳杆菌LP-116的16S rDNA序列为SEQ IDNO:1,扩增得到16S rDNA序列长度为1454bp;其16S rDNA序列在NCBI中进行同源性比对后发现,该菌株与副干酪乳杆菌属具有100%同源性,结果显示该菌株属于副干酪乳杆菌属。
热灭活副干酪乳杆菌(后生元)菌粉的制备
采用MRS肉汤培养基培养副干酪乳杆菌LP-116,接种量为1%(v/v),培养时间24小时,培养完成后4℃、8000 r/min离心10 min,无菌蒸馏水冲洗菌体两次后重悬菌体,在100℃条件下灭菌30 min。
副干酪乳杆菌LP-116菌悬液灭活前后分别取样,用无菌生理盐水(0.9%)稀释涂布MRS固体培养基,在37℃恒温培养箱静止培养48 h进行平板计数,检测灭活效果。经热处理后的平板没有菌落长出,则表明灭活成功。
将灭活菌体悬液置于无菌平皿中于-40℃冷冻干燥并称重,热灭活副干酪乳杆菌(后生元)菌粉中副干酪乳杆菌个数为1012CFU/g。
微生物制剂的制备
鼠李糖乳杆菌GG株(LGG益生菌)购自科汉森(北京)贸易有限公司;
长双歧杆菌BL21购自微康益生菌(苏州)股份有限公司;
微生物制剂由50%益生菌冻干粉和50%益生元所组成,其中益生元包括麦芽糊精、菊粉和低聚半乳糖;
微生物制剂1:25%灭活副干酪乳杆菌LP-116冻干粉(菌数为1012CFU/g)、25%灭活鼠李糖乳杆菌GG株冻干粉(菌数为1012CFU/g)、15%麦芽糊精、20%菊粉和15%低聚半乳糖。
微生物制剂2:25%灭活副干酪乳杆菌LP-116冻干粉(菌数为1012CFU/g)、25%灭活长双歧杆菌BL21冻干粉(菌数为1012CFU/g)、15%麦芽糊精、20%菊粉和15%低聚半乳糖。
微生物制剂3:50%灭活副干酪乳杆菌LP-116冻干粉(菌数为1012CFU/g)、15%麦芽糊精、20%菊粉和15%低聚半乳糖。
微生物制剂4:50%未灭活副干酪乳杆菌LP-116冻干粉(菌数为1012CFU/g)、15%麦芽糊精、20%菊粉和15%低聚半乳糖。
本发明中所使用的试剂及材料如下:Caco-2人结直肠腺癌细胞株来源于武汉普普诺赛生命科技有限公司(中国)。脂多糖(LPS)和荧光素异硫氰酸酯(FITC)购自Sigma-Aldrich公司(美国)。其它细胞培养材料均购自上海逍鹏生物科技有限公司(中国),包括胎牛血清(FBS)、DMEM高糖培养基、青霉素链霉素双抗、胰蛋白酶、Hanks'平衡盐溶液(HBSS)和磷酸盐缓冲盐溶液(PBS)。内参β-actin(货号:66009-1-Ig),MyD88(货号:23230-1-AP),TLR4(货号:19811-1-AP),NF-κB p65(货号:10745-1-AP),Claudin-1(货号:13050-1-AP),Occludin(货号:27260-1-AP),ZO-1(货号:21773-1-AP),MLCK(货号:21642-1-AP),MLC(货号:10906-1-AP),HRP-conjugated Affinipure Goat Anti-Mouse IgG(货号:SA00001-1),HRP-conjugated Affinipure Goat Anti-Rabbit IgG(货号:SA00001-2),CoraLite488-conjugated Goat Anti-Rabbit IgG(货号:SA00013-2),CoraLite594-conjugated GoatAnti-Rabbit IgG(货号:SA00013-4)购自proteintech Group生物技术有限公司(中国),Phospho-MLC(Thr18/Ser19)(货号:3674)和Phospho-NFκB p65(货号:Ser536)(3033)购自Cell Signaling Technology(美国)。
试验1:微生物制剂对Caco-2细胞活性的影响
Caco-2细胞培养过程如下:将细胞置于DMEM完全培养液(含10%胎牛血清、1%的双抗、1%谷氨酰胺、1%非必需氨基酸)中,37℃、5% CO2培养箱中培养,每隔1-2天更换一次培养基,待细胞融合至90%时,用胰酶消化传代、并进行后续相关实验。
取对数生长期的Caco-2细胞按照1×105个/mL的密度接种于96孔板,每孔100 μL,置于37°C、5% CO2培养箱中培养至形成细胞单层,弃掉培养液,加入100 μL,1 μg/mL的微生物制剂和终浓度100 μg/mL LPS与细胞共孵育24 h后,弃掉培养液,DMEM冲洗一次,CCK-8法测定每孔的吸光值,并计算各孔的相对细胞活性(%)。
同时设置LPS组(只添加浓度100 μg/mL的LPS)和空白对照组(Control组,不添加微生物制剂和LPS)。
试验结果如图3所示,浓度为100 μg/mL的LPS在刺激24小时后可显著降低Caco-2细胞活力,活力降低至68.24%,通过添加灭活副干酪乳杆菌LP-116可有效地提高Caco-2细胞活力。同时,实验还发现灭活副干酪乳杆菌LP-116和灭活鼠李糖乳杆菌GG株复配(微生物制剂1),相比于灭活副干酪乳杆菌LP-116和灭活长双歧杆菌BL21复配(微生物制剂2),能明显提高Caco-2细胞活力接近20%。通过对比微生物制剂1与微生物制剂3缓解由LPS诱导Caco-2细胞凋亡能力发现,50%灭活副干酪乳杆菌LP-116冻干粉并没有25%灭活副干酪乳杆菌LP-116冻干粉+25%灭活鼠李糖乳杆菌GG株冻干粉缓解细胞毒性能力强,说明热灭活LP-116与热灭活鼠李糖乳杆菌GG株协同效果优于单独地热灭活LP-116冻干粉。
试验2:微生物制剂对肠上皮屏障细胞间跨膜电阻和通透性的影响
Caco-2细胞的培养和消化传代参照试验1中的步骤,以1×104cells/cm2的密度接种到12孔transwell(Corning, Lindfield, Sydney, Australia)细胞培养室中,培养21天,待Caco-2细胞完全分化且电阻值达到500 Ω/cm2以上时,可用于进一步的实验,LPS是革兰氏阴性菌的重要组成部分,可改变肠上皮细胞的通透性和电阻性,在transwell培养板中培养的Caco-2细胞构建细胞单层,可以通过LPS诱导进而建立肠屏障功能障碍模型,采用评估TEER值和FITC-葡聚糖转运,以确定微生物制剂是否可以改善由LPS引起的肠道屏障功能损伤。
取100μL浓度(终浓度1μg/mL)的微生物制剂加入到细胞单层黏膜侧,同时加入LPS(终浓度100 μg/mL)共同作用24 h,测定各孔的最终TEER值。此外,为了评价Caco-2细胞单层模型的紧密性和渗透性,将FITC-葡聚糖作为细胞转运标记物,加入100 μL的FITC-葡聚糖(终浓度为1 mg/mL)到细胞单层黏膜侧,置于37°C、5% CO2培养箱内孵育24小时。
同时设置LPS组(只添加浓度100 μg/mL的LPS)和空白对照组(Control组,不加微生物制剂和LPS),孵育完成后,分别移取各组细胞单层浆膜侧内100μL的培养液于黑色的96孔板中,快速置于酶标仪于激发波长为480 nm、发射波长为520 nm的条件下测定各组的荧光强度。
试验结果如图4所示,LPS组(100 μg/mL)的电阻值和通透性与Control组具有显著性差异(P<0.05),说明LPS可以明显引起Caco-2肠上皮屏障细胞损伤。相比较于LPS组,添加灭活副干酪乳杆菌LP-116冻干粉的微生物制剂组可以不同程度地缓解由LPS诱导引起的肠屏障功能损伤。其中微生物制剂1缓解的效果最好,并与LPS组具有显著性差异(P<0.05)。通过比较4种微生物制剂缓解LPS诱导引起的肠屏障功能损伤能力来看,微生物制剂1的效果同样优于其它3种制剂,说明灭活副干酪乳杆菌LP-116冻干粉与灭活鼠李糖乳杆菌GG株冻干粉进行复配后的益生效果优于单独作用。
试验3:微生物制剂对Caco-2细胞促炎症因子水平的影响
采用ELISA法对Caco-2细胞内TNF-α、IL-1β、IL-6分泌水平进行检测,取对数期Caco-2细胞接种于6孔板,每孔2×105个细胞,于37°C、5% CO2培养箱中培养细胞融合至90%,弃掉培养液后,取1000μL浓度(终浓度1μg/mL)的微生物制剂加入6孔板中,同时加入LPS(终浓度100μg/mL)共同作用24 h。
同时设置LPS组(只添加浓度100 μg/mL的LPS)和空白对照组(Control组,不加微生物制剂和LPS),取浆膜侧溶液按照试剂盒说明书流程进行操作后,使用酶标仪在450 nm下读OD值,根据产品说明书及实验数据制作标准曲线,用ELISA数据处理软件拟合标准曲线,同时计算各组中的TNF-α、IL-1β、IL-6含量。
试验结果如图5所示,通过ELISA试剂盒检测诱导的Caco-2细胞单分子层中TNF-α、IL-1β、IL-6含量可知,LPS能够显著诱导Caco-2细胞分泌炎症因子(P<0.01)。结合LPS对照组、微生物制剂组和空白对照组可知,微生物制剂1-4组中的促炎因子分泌含量均低于LPS组,说明微生物制剂可有效缓解LPS诱导的炎症因子分泌,从而达到缓解炎症发生。通过分析对比微生物制剂之间促炎因子分泌情况,发现微生物制剂1组中的促炎因子分泌情况低于其他微生物制剂2~4,并且灭活副干酪乳杆菌LP-116冻干粉与灭活鼠李糖乳杆菌GG株进行复配后(微生物制剂1)缓解Caco-2炎症发生的效果优于灭活副干酪乳杆菌LP-116冻干粉与灭活BL21冻干粉复配(微生物制剂2)。
试验4:Western blot检测微生物制剂对Caco-2细胞内目标蛋白表达水平
采用Western blot法分析Caco-2细胞全蛋白中目标蛋白的表达,步骤如下:细胞培养和实验分组与试验3中一致,刺激完成后加入1.5 mL预冷的无菌PBS将细胞刮下收集至1.5 mL的EP管中,离心(8000 r/min,4°C)5 min后获得细胞沉淀,向各EP管中加入含有蛋白酶抑制剂的RIPA(强)细胞裂解液,吹打均匀使细胞充***解后对目标蛋白的表达水平进行检测。
将含细胞裂解液的EP管放入离心机离心(12000 r/min,4°C)15 min后,移取各细胞蛋白上清液,BCA法确定各组蛋白浓度,分别移取等量蛋白的上清液与上样缓冲液,按照比例混合均匀,沸水浴5 min使蛋白充分变性,待样品冷却后,用移液器将混合液加入到各泳道进行聚丙烯酰胺凝胶电泳分离、转膜,将带有目的蛋白的硝酸纤维膜放于5%脱脂牛奶中室温封闭1 h,孵育各蛋白对应的一抗,4°C条件下过夜后,将一抗回收,同时将蛋白条带用TBST溶液室温下洗涤3次,用相应二抗室温下孵育蛋白条带1 h后,再用TBST溶液洗涤条带3次,将蛋白条带置于暗室进行化学发光、压片,X射线胶片曝光显影。
凝胶成像***采集图片结果,并用Image J软件计算各蛋白条带的灰度值,检测指标包括NF-κB信号通路中TLR-4、p-NFκB、NFκB和紧密连接蛋白ZO-1、claudin-1、occludin以及MLCK、MLC和p-MLC蛋白水平。
试验结果如图6所示,参考图6(A)中Control组和LPS组可知,经LPS的刺激,Caco-2细胞内TLR4和p-NFκB蛋白的表达显著提高,说明LPS能够显著诱导Caco-2细胞提高TLR4和p-NFκB蛋白(P <0.05)。结合LPS组、微生物制剂组和Control组可知,微生物制剂1组中TLR-4和p-NFκB蛋白含量最低,表明微生物制剂1相比于其它制剂具有更好缓解由LPS引发的炎症。
参考图6(B),结合Control组和LPS组可知,LPS刺激Caco-2细胞内p-MLC和MLCK蛋白的表达显著提高(P <0.05)。结合LPS组、微生物制剂组和Control组可知,微生物制剂1组中p-MLC和MLCK蛋白含量最低,并且微生物制剂1在p-MLC蛋白含量显著低于其它3组微生物制剂,表明灭活副干酪乳杆菌LP-116与灭活鼠李糖乳杆菌GG株复配后的效果最好,降低了由LPS引发的炎症通路。
参考图6(C),结合Control组和LPS组可知,经LPS的刺激,Caco-2细胞内TJ蛋白的表达量降低,可见LPS能够抑制Caco-2细胞的TJ蛋白表达能力(P <0.05)。通过对比四种微生物制剂改善肠道屏障功能损伤能力发现,微生物制剂1~3组均能改善TJ蛋白,而微生物制剂4组改善效果最差,说明添加了灭活副干酪乳杆菌LP-116均能在不同程度下修复肠道屏障。此外,通过比较灭活副干酪乳杆菌LP-116冻干粉分别与灭活鼠李糖乳杆菌GG株冻干粉和BL21冻干粉复配后的改善效果发现,LP-116冻干粉与灭活鼠李糖乳杆菌GG株冻干粉复配后具有较佳的改善效果。
试验5:实时荧光定量PCR检测炎症因子及ZO-1、claudin-1、occludin基因表达
采用实时荧光定量PCR检测炎症因子及ZO-1、claudin-1、occludin基因表达,步骤如下:细胞培养和实验分组与试验3中一致,刺激完成后加入1.5 mL预冷的无菌PBS将细胞刮下收集至1.5 mL的EP管中,离心(8000 r/min,4°C)5 min后获得细胞沉淀,加入500 μLTrizol裂解10 min,剧烈震荡后在室温条件下放置5 min以使核蛋白体完全解离,4℃的条件下以12,000 rpm离心10 min取上清;按照每1 mL Trizol加入0.2 mL氯仿,剧烈震荡15 s后室温下放置2~3 min,于4℃ 12000 rpm高速冷冻离心10~15 min,离心后将上层水相转移到干净的EP管中,加入等体积异丙醇,颠倒混匀后室温放置10 min后离心弃上清,离心条件同上,用与Trizol使用量相同体积的75 %乙醇对沉淀进行洗涤,吹打至RNA沉淀轻轻悬浮,但不要吹散,4℃ 12000 rpm离心3 min,弃上清,注意不要丢失RNA沉淀,室温放置2~3 min,晾干,加入50 μL无酶水,充分溶解RNA,得到的RNA保存在-80℃,防止降解。
核酸定量仪测定OD值定量RNA浓度,用无酶水将各样品RNA稀释到同一浓度。按照康为试剂HiFiScript cDNA Synthesis Kit说明书配制反转录体系,去除基因组DNA条件为42℃孵育2 min,cDNA合成反应条件为42℃孵育15 min,85℃孵育5 min,反应结束后短暂离心于-20℃保存。
qPCR操作步骤按照康为试剂公司的UltraSYBR Mixture说明书进行荧光定量,扩增条件为预变性95°C 10 min,然后变性95°C 15 s和退火/延伸60°C 1 min进行40个循环,融解条件95°C 15s,60°C 1 min,95°C 15s,60°C 15s。首先用内参基因的Ct值对实验组(test)和对照组(control)的靶基因Ct值进行归一化;ΔCt test=实验组目的基因Ct值-实验组内参基因Ct值,ΔCt control=对照组目的基因Ct值-对照组内参基因Ct值,目的基因表达水平差异倍数=2-(ΔCt test-ΔCt control)。检测指标包括促炎因子(TNF-α、IL-1β、IL-6)以及ZO-1、claudin-1、occludin基因表达。
表4: RT-qPCR引物序列表
试验结果如图7所示,LPS组(100 μg/mL)的促炎症因子TNF-α、IL-1β、IL-6的mRNA表达量相比较于Control组显著提高(P<0.05)。相比较于LPS组,添加灭活副干酪乳杆菌LP-116冻干粉的微生物制剂组可以不同程度地缓解由LPS诱导引起的促炎因子mRNA表达量。其中微生物制剂1缓解的效果最好,并与LPS组具有显著性差异(P<0.05)。通过比较4种微生物制剂缓解LPS诱导引起的肠屏障功能损伤能力(ZO-1、Occludin、Claudin-1)来看,微生物制剂1的效果同样优于其它3种微生物制剂,说明灭活副干酪乳杆菌LP-116冻干粉与灭活鼠李糖乳杆菌GG株冻干粉进行复配后的益生效果优于单独作用。
试验6:免疫荧光观察TJ蛋白表达
取对数期Caco-2细胞,调整细胞浓度至1.0×104个/孔接种于24孔板培养皿中于37°C、5% CO2培养箱中培养细胞融合至80%。将终浓度1 μg/mL微生物制剂1和LPS刺激共同刺激Caco-2细胞24 h后,弃掉细胞培养液,PBS洗涤三次,4%多聚甲醛固定20 min,再用0.5%TritonX-100通透20 min,5% FBS溶液室温封闭15 min,按照1:100的比例配制ZO-1一抗溶液,4℃过夜;荧光二抗室温孵育1 小时,DAPI染核,室温10 min,甘油PBS封片观察、拍照。
试验结果如图8所示,LPS组(100μg/mL)能引起肠道损伤能力(ZO-1、Occludin、Claudin-1),而微生物制剂1的效果能改善这一现象,说明灭活副干酪乳杆菌LP-116冻干粉与灭活鼠李糖乳杆菌GG株冻干粉进行复配后,有益于肠道屏障改善。
试验7:细胞内NF-κB p65核转位观察
倒置荧光显微镜下观察并记录NF-κB p65的入核情况。具体如下:取对数期Caco-2细胞,调整细胞浓度至1.0×103个/孔接种于24孔板培养皿中于37°C、5% CO2培养箱中培养细胞融合至80%,用1μg/mL微生物制剂1孵育细胞6 h,再用LPS刺激细胞24 h后,按照NF-κB检测试剂盒说明书步骤处理细胞,倒置荧光显微镜下观察并记录NF-κB p65的入核情况。
试验结果如图9所示,LPS组(100μg/mL)能加剧炎症反应,而微生物制剂1的效果能改善这一现象,进一步说明灭活副干酪乳杆菌LP-116冻干粉与灭活鼠李糖乳杆菌GG株冻干粉进行复配后的有益效果。
最后需要说明的是:以上实施例不以任何形式限制本发明。对本领域技术人员来说,在本发明基础上,可以对其作一些修改和改进。因此,凡在不偏离本发明精神的基础上所做的任何修改或改进,均属于本发明要求保护的范围之内。
Claims (9)
1.一种副干酪乳杆菌LP-116,其特征在于,该菌株保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏号为CGMCC NO.20266,保藏地址为北京市朝阳区北辰西路1号院3号,拉丁文名称为Lactobacillus paracasei。
2.一种调节肠道屏障受损的微生物制剂,其特征在于,包括如权利要求1所述的副干酪乳杆菌LP-116和LGG益生菌。
3.根据权利要求2所述的调节肠道屏障受损的微生物制剂,其特征在于,副干酪乳杆菌LP-116和LGG益生菌的重量比为1-3:1。
4.根据权利要求2所述的调节肠道屏障受损的微生物制剂,其特征在于,微生物制剂的活性成分为副干酪乳杆菌LP-116的灭活型菌体以及LGG益生菌的灭活型菌体。
5.根据权利要求2所述的调节肠道屏障受损的微生物制剂,其特征在于,所述微生物制剂为益生菌冻干粉,还包括益生元。
6.根据权利要求5所述的调节肠道屏障受损的微生物制剂,其特征在于,益生菌冻干粉和益生元的质量比为4-6:4-6。
7.根据权利要求5所述的调节肠道屏障受损的微生物制剂,其特征在于,所述益生元包括麦芽糊精、菊粉和低聚半乳糖。
8.根据权利要求7所述的调节肠道屏障受损的微生物制剂,其特征在于,麦芽糊精、菊粉和低聚半乳糖的质量比为1-2:1-2:1。
9.根据权利要求2所述的调节肠道屏障受损的微生物制剂,其特征在于,所述微生物的剂型包括片剂、口服液或胶囊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410069815.9A CN117603885B (zh) | 2024-01-18 | 2024-01-18 | 一种副干酪乳杆菌lp-116及其在制备调节肠道屏障受损产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410069815.9A CN117603885B (zh) | 2024-01-18 | 2024-01-18 | 一种副干酪乳杆菌lp-116及其在制备调节肠道屏障受损产品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117603885A CN117603885A (zh) | 2024-02-27 |
CN117603885B true CN117603885B (zh) | 2024-04-05 |
Family
ID=89950189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410069815.9A Active CN117603885B (zh) | 2024-01-18 | 2024-01-18 | 一种副干酪乳杆菌lp-116及其在制备调节肠道屏障受损产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117603885B (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190111582A (ko) * | 2018-03-23 | 2019-10-02 | (주)바이오일레븐 | 염증성 장질환의 치료 또는 예방을 위한 락토바실러스 파라카제이 균주 |
CN111802649A (zh) * | 2020-04-14 | 2020-10-23 | 河北弗蒙特生物科技有限公司 | 一种含免疫调节肽功能成分的lgg发酵产物的制备方法及其应用 |
CN112869169A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌et-22提升肠道细菌感染抗性和肠道免疫力的应用 |
CN114085792A (zh) * | 2021-11-17 | 2022-02-25 | 哈尔滨医科大学 | 一种用于防治结肠癌的副干酪乳杆菌及其应用 |
CN115300531A (zh) * | 2022-09-02 | 2022-11-08 | 东北农业大学 | 一种副干酪乳杆菌jy062组合物及其制备方法和应用 |
CN115786198A (zh) * | 2022-11-25 | 2023-03-14 | 四川大学 | 一株副干酪乳杆菌及其应用 |
CN116218703A (zh) * | 2022-10-31 | 2023-06-06 | 东北农业大学 | 一株植物乳杆菌、具肠道粘附力的组合物及其制法和作为高脂饮食肠道屏障保护剂的应用 |
CN116769682A (zh) * | 2023-08-22 | 2023-09-19 | 东北农业大学 | 缓解食物过敏的副干酪乳杆菌jy56后生元及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110959865B (zh) * | 2018-09-30 | 2021-07-09 | 内蒙古伊利实业集团股份有限公司 | 可调节胃肠道菌群平衡的副干酪乳杆菌k56的新应用 |
CN111944725B (zh) * | 2020-08-24 | 2021-12-07 | 汤臣倍健股份有限公司 | 一种副干酪乳杆菌207-27及其应用 |
TWI802194B (zh) * | 2021-07-13 | 2023-05-11 | 大江生醫股份有限公司 | 諾麗果發酵物於製備改善體態及肌膚狀況之組合物之用途 |
-
2024
- 2024-01-18 CN CN202410069815.9A patent/CN117603885B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190111582A (ko) * | 2018-03-23 | 2019-10-02 | (주)바이오일레븐 | 염증성 장질환의 치료 또는 예방을 위한 락토바실러스 파라카제이 균주 |
CN112869169A (zh) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌et-22提升肠道细菌感染抗性和肠道免疫力的应用 |
CN111802649A (zh) * | 2020-04-14 | 2020-10-23 | 河北弗蒙特生物科技有限公司 | 一种含免疫调节肽功能成分的lgg发酵产物的制备方法及其应用 |
CN114085792A (zh) * | 2021-11-17 | 2022-02-25 | 哈尔滨医科大学 | 一种用于防治结肠癌的副干酪乳杆菌及其应用 |
CN115300531A (zh) * | 2022-09-02 | 2022-11-08 | 东北农业大学 | 一种副干酪乳杆菌jy062组合物及其制备方法和应用 |
CN116218703A (zh) * | 2022-10-31 | 2023-06-06 | 东北农业大学 | 一株植物乳杆菌、具肠道粘附力的组合物及其制法和作为高脂饮食肠道屏障保护剂的应用 |
CN115786198A (zh) * | 2022-11-25 | 2023-03-14 | 四川大学 | 一株副干酪乳杆菌及其应用 |
CN116769682A (zh) * | 2023-08-22 | 2023-09-19 | 东北农业大学 | 缓解食物过敏的副干酪乳杆菌jy56后生元及其应用 |
Non-Patent Citations (2)
Title |
---|
Heat-Killed Lacticaseibacillus paracasei Repairs Lipopolysaccharide-Induced Intestinal Epithelial Barrier Damage via MLCK/MLC Pathway Activation;Zhixin Xie等;《nutrients》;20230430;第15卷(第7期);第1-19页 * |
戊糖乳杆菌LS1细菌素的分离纯化及性质鉴定;李志如等;《食品科学》;20191029;第41卷(第20期);第112-118页 * |
Also Published As
Publication number | Publication date |
---|---|
CN117603885A (zh) | 2024-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111484957B (zh) | 动物双歧杆菌乳亚种i797、其分离纯化方法及应用 | |
EP2179028B1 (en) | A novel strain of bifidobacterium and active peptides against rotavirus infections | |
CN113604384B (zh) | 一种鼠李糖乳杆菌及其应用 | |
CN112625979B (zh) | 一种对抗幽门螺杆菌的干酪乳杆菌及其应用 | |
CN110144310B (zh) | 一株具有缓解肠炎和促进肠道发育作用的枯草芽孢杆菌和应用 | |
CN116396890B (zh) | 用于防治结肠癌的植物乳杆菌zjuids15及其应用 | |
WO2022110282A1 (zh) | 长双歧杆菌长亚种i772、其分离纯化方法及应用 | |
CN111117925B (zh) | Anaerostipes sp B2131菌及其在炎症性肠病中的应用 | |
CN115029260B (zh) | 一种具有抗炎及抗氧化特性的格氏乳杆菌及应用 | |
CN112940985A (zh) | 一种增强人体免疫力的鼠李糖乳杆菌制剂及其制备方法 | |
CN114317334B (zh) | 一株能够与幽门螺杆菌共聚集的清酒乳杆菌及其应用 | |
CN116200290A (zh) | 一种具有抑制结直肠癌细胞增殖的副干酪乳酪杆菌及其应用 | |
US20230321163A1 (en) | Composition For Treating or Preventing Clostridium Difficile Infection | |
KR100435505B1 (ko) | 김치에서 분리된 헬리코박터 필로리의 부착과성장억제성능 락토바실러스 플란타룸 | |
CN117603885B (zh) | 一种副干酪乳杆菌lp-116及其在制备调节肠道屏障受损产品中的应用 | |
CN117143767A (zh) | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 | |
CN115044504B (zh) | 一株粪肠球菌yz-1及其益生性应用 | |
CN115590893A (zh) | 一种可抑制幽门螺杆菌的复合益生菌组合物及其应用 | |
RU2584600C2 (ru) | ШТАММ L.bulgaricus, СПОСОБНЫЙ ИНГИБИРОВАТЬ АДГЕЗИЮ ШТАММОВ Н.pylori К ЭПИТЕЛИАЛЬНЫМ КЛЕТКАМ | |
CN110938563B (zh) | 一种乳酸菌bj-reborn001及其在制备抑制幽门螺旋杆菌的发酵液中的应用 | |
CN117586926B (zh) | 副干酪乳杆菌lp-116、lp-116后生元组合物及其制备方法与应用 | |
CN113604383B (zh) | 一种干酪乳杆菌及其应用 | |
RU2803350C1 (ru) | Штамм бактерий Bifidobacterium longum 174 для приготовления регион-специфичных пробиотических препаратов для профилактики и персонализированного лечения заболеваний желудочно-кишечного тракта у жителей Карачаево-Черкесской республики и/или для обогащения традиционного кисломолочного напитка "Гыпы айран" на основе индигенных кефирных зерен | |
CN114015598B (zh) | 分离自藏灵菇的乳酸片球菌及其在防治轮状病毒感染中的应用 | |
CN115109718B (zh) | 一株屎肠球菌菌株及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |